Alphamab Oncology to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

December 26th, 2021 (Shanghai) — We are glad to announce that Ting Xu, the Chairman, CEO of Alphamab Oncology, has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

If you are interested in listening to the live event, please register at https://biotochina.org/register/

About Alphamab Oncology

Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of innovative biotherapeutics for cancer treatment. With multiple in-house proprietary platforms of bispecifics, protein engineering and antibody screening, the company have built a robust pipeline in oncology and immunology with more than 20 phase II-III clinical trials running globally.

About the speaker

Dr. Xu has more than 20 years of experience in pharmaceutical research and development. He worked at Archemix, Serono and Biogen as Principal Investigator or Project Leader, founded Suzhou Alphamab in 2008 and Jiangsu Alphamab, which listed in HK in 2019.
Dr. Xu has extensive experiences in protein engineering, antibody drug screening and engineering, and CMC etc. Several drugs which Dr. Xu previously was involved in the development have been marketed or in clinical development stage in Europe and the United States. After returning to China, he has established several proprietary protein and antibody engineering platforms, successfully developed more than 20 innovative biological drug candidates and more than 30 biosimilar drug candidates.
Dr. Xu obtained his bachelor’s degree in biochemistry from Nanjing University, doctoral degree from the Chinese Academy of Sciences, was a post-doctoral fellow at Harvard University， and holds adjunct professorship in Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, and Southeast University. He has applied more than 100 patents, been recognized by many awards including”2018 Jiangsu Top Ten Science and Technology Innovation and Entrepreneurship Figures”.

About ACCESS CHINA

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

More information